Cases & Deals

Cellectis completes acquisition of Cellartis and €50 million private placement and issues free share purchase warrants to existing shareholders

Clients Cellectis SA

Jones Day advised Cellectis SA, a world leader in genome engineering listed on the Alternext market of NYSE Euronext Paris, in connection with the €33.8 million acquisition of Cellartis, the European stem cell leader, in conjunction with the €50 million private placement of convertible bonds evenly subscribed by the Fonds Stratégique d'Investissement (FSI) and Pierre Bastid and the issuance of free share purchase warrants to existing shareholders.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.